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Abstract
Malignant rhabdoid tumors (MRTs) are rare, aggressive cancers occuring in young children
primarily through inactivation of the SNF5(INI1, SMARCB1) tumor suppressor gene. We and
others have demonstrated that mice heterozygous for a Snf5 null allele develop MRTs with partial
penetrance. We have also shown that Snf5+/− mice that lack expression of the pRb family, due to
TgT121 transgene expression, develop MRTs with increased penetrance and decreased latency.
Here, we report that altering the genetic background has substantial effects upon MRT
development in Snf5+/− and TgT121;Snf5+/− mice, with a mixed F1 background resulting in
increased latency and the appearance of brain tumors. We also report the establishment of the first
mouse MRT cell lines that recapitulate many features of their human counterparts. Our studies
provide further insight into the genetic influences on MRT development as well as provide
valuable new cell culture and genetically engineered mouse models for the study of CNS-MRT
etiology.
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Introduction
Malignant rhabdoid tumors (MRTs) are highly aggressive pediatric malignancies that can
arise in the kidneys and soft tissues throughout the body, as well as in the central nervous
system, where they are referred to as atypical teratoid/rhabdoid tumors or AT/RTs 1. Patients
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may develop more than one primary tumor as approximately 10–15% of patients with renal
MRTs also develop independent primary tumors of the CNS 2. These cancers are extremely
aggressive, with most patients perishing within one year of diagnosis 3. Therefore, new
treatment approaches for this disease remain a high priority.
Rhabdoid cells have distinctive cellular characteristics including large vesicular nuclei, a
prominent single nucleolus, and globular eosinophilic cytoplasmic inclusions. Because
MRTs typically consist of poorly differentiated cells with a few admixed rhabdoid cells,
diagnosis based on histology alone has proven difficult. However, recent studies have shown
that virtually all MRTs lose expression of the SNF5/INI1/BAF47/SMARCB1 gene
providing a useful diagnostic marker 4, 5. The SNF5 gene, which encodes the smallest
member of the SWI/SNF chromatin remodeling complex, localizes to 22q11.2. The SNF5
protein interacts with many transcription regulators and viral proteins, such as c-MYC, p53
and HIV-IN 6. The SNF5 protein is highly conserved among different species with complete
identity between mouse and human proteins 7.
In mice, Snf5-deficiency results in embryonic lethality by E6.5, while ~15% of Snf5+/− mice
develop rhabdoid-like tumors at 8–10 months of age 8. Conditional Snf5 inactivation results
in complete bone marrow aplasia leading to anemia, hemorrhage and death of most mice 1–
3 weeks after induction 9. Furthermore, SNF5 appears essential for hepatocyte
differentiation based on the phenotype of hepatocyte-specific Snf5 deletion in utero 10.
These data demonstrate that Snf5 is not only an MRT tumor suppressor, but also plays a
critical role in both organ and cell differentiation.
Re-expression of SNF5 in SNF5-deficient human MRT cell lines reduces phosphorylation of
the retinoblastoma protein (pRb) through activation of p16INK4a transcription and/or
inhibition of cyclin D1 expression, leading to suppression of activating E2Fs 8. The Rb/E2F
pathway regulates cell cycle progression and plays an important role in a wide array of
human cancers 11, 12. A recent in vivo study also suggests that Rb is epistatic to SNF5 in
tumor suppression 13.
Previous studies suggest that SNF5 loss might also contribute to the development of choroid
plexus carcinoma (CPC) 14, 15, a rare pediatric tumor of the active transport epithelium
located in the brain ventricles. However, since MRTs often develop in similar locations and
can be difficult to diagnose based on histology alone, there is some debate as to whether
MRTs and CPCs are distinct tumors both impacted by SNF5 inactivation, tumor types that
share a common origin, or unrelated tumors with histological similarities that cloud
diagnosis (see Discussion). Therefore, we utilized a genetically engineered mouse model
(GEMM), TgT121, in which CPCs develop with high frequency to investigate whether loss
of SNF5 contributes to CPC progression.
TgT121 mice express a truncated SV40 large T antigen (T121) that inactivates pRb and
related proteins p107 and p130 (but not p53) under the control of the lymphotropic
papovavirus (LPV) promoter 16. Transgene expression is robust in the choroid plexus
epithelium (CPE), predisposing to CPC, and in B and T lymphoid cells without
consequence 16, 17. Dominant interference of pRb, p107 and p130 by T121 is an effective
strategy for complete inactivation of pRb family (pRbf) function in the mouse due to
compensation of pRb inactivation by p107 and/or p130 18–20. TgT121 mice develop CPCs
upon spontaneous CPE p53 inactivation and become terminal around 7 months of age 21, 22.
Here, to examine the combined effects of pRbf and SNF5 inactivation and to determine the
relationship (if any) between CPC and MRT, we analyzed development of these tumor types
in TgT121;Snf5+/− mice. We report interesting tumor-specific differences in the
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cooperativity of these events. The results further provide insight into the MRT target cell
type and the relationship between CPCs and MRTs.
Materials and Methods
Generation of TgT121;Snf5+/− Mice
The generation, screening and characterization of TgT121 transgenic and Snf5+/− mice were
described previously16, 21, 23. TgT121 mice were maintained on a BDF1 (Jackson Labs)
background. We backcrossed the Snf5+/− mice to C57BL/6 mice for at least 9 generations to
produce congenic Snf5+/− mice. TgT121;Snf5+/− mice were derived by crossing TgT121 mice
with Snf5+/− mice and using only F1 generation mice. Mice with resulting genotypes,
TgT121, Snf5+/−, TgT121;Snf5+/− and TgT121;Snf5+/+ were born with the expected
Mendelian frequencies. All procedures approved by the Institutional Animal Care and Use
Committees.
Genotyping
Mice were genotyped by PCR amplification of genomic DNA from either mouse tails or cell
lines. Mouse genomic DNA was extracted by incubating tissues with buffer A (0.2 mM
EDTA pH 8.0 and 25 mM NaOH) at 95°C for 1 hr. The lysate was neutralized by the same
volume of buffer B (40 mM Tris-HCl) followed by vigorous vortexing. Debris was pelleted
and the supernatant was used in PCR amplification. PCR was performed using the EasyStart
50 PCR Kit (Molecular Bio-Products Inc., San Diego, CA). The wild type Snf5 allele were
detected using primers against a sequence before exon 1 (Snf5-01 5’-
CACCATGCCCCCACCTCCCCTACA-3’) and exon 1 (Snf5-02 5’-
CAGGAAAATGGATGCAACTAAGAT-3’), while the Snf5 null allele was amplified using
primers against the neo insert (in exons 1–2; 5’-GGCCAGCTCATTCCTCCCACTCAT-3’)
and Snf5-01. T121 positive animals were detected by using primers : 5’-
GAATCTTTGCAGCTAATGGACC-3’ and 5’-GCATCCCAGAAGCTCCAAAG-3’. PCR
conditions were: 94°C 1 min, 61 °C or 59°C 2 min and 72°C 1 min for 35 cycles. Agarose
gel electrophoresis was used to detect the PCR products.
Genomic DNA isolation and LOH analysis of Snf5
Tumor DNA was isolated from frozen tumor samples or from paraffin embedded tissue
slices by using the DNeasy tissue kit (Qiagen, Valencia, CA). For primary tumors, samples
were crushed into a fine power under liquid nitrogen prior to DNA isolation. Amplification
of the Snf5 wild type and null alleles by PCR was performed using the EasyStart 50 PCR
Kit (Molecular Bio-Products Inc., San Diego, CA) using the conditions described above.
Western blot analysis
Western blotting was carried out as previously described 24. Briefly, protein concentration
was quantified by the Bio-Rad protein assay (Bio-Rad Laboratories, Hercules, CA). Thirty-
five µg of protein were separated by electrophoresis on 4–20% SDS-polyacrylamide gels
(Cambrex, East Rutherford, NJ) and electro-transferred onto Immobilon-P membranes
(Millipore, Billerica, MA) as per manufacturers’ directions. Western analyses of proteins
were carried out by using anti-p16INK4a (1:500, G175–1239, Pharmingen, San Diego, CA),
anti-smooth muscle actin (1:200, Clone 1A4, Sigma, St. Louis, MO), anti-SV40 T antigen
(1:1000, Pab416, Calbiochem, Darmstadt, Germany), anti-BAF180 (1:2000, kind gift of Dr.
Ramon Parsons, Columbia University), anti-Nestin (1:5000, sc23929, SCBT, Santa Cruz,
CA), anti-SOX2 (1:3000, AB5603, Millipore, Billerica, MA), anti-p18INK4C (1:1000, a kind
gift from Dr. Xue Xiong, UNC-Chapel Hill), SNF5 (1:1000, 612110, BD Biosciences, San
Jose, CA), anti-β-actin (1:4000, A2066, Sigma, St. Louis, MO), and 1:2000 horseradish
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peroxidase conjugated anti-rabbit or anti-mouse IgG (Amersham, Piscataway, NJ).
Individual proteins were detected with ECL chemiluminescense reagent (Amersham,
Piscataway, NJ) on Biomax ML film (Kodak, Rochester, NY).
Histopathology and Immunohistochemistry
Brain and facial tumors were fixed in 10% formalin for 16–20 hrs, washed in running water
for 3 min and saved in 70% ethanol. Tissues were routinely processed and embedded, and 5
µM sections were stained with hematoxylin and eosin (H&E) or immunohistochemistry
(IHC) as described. For IHC, antigen retrieval was performed with 1.0 mM EDTA, pH 8.0
(Zymed, South San Francisco, CA) in a steam pressure cooker at 125 °C for 30 seconds
followed by a cool down set point at 90 °C for 10 seconds (Decloaking Chamber, BioCare
Medical, Walnut Creek, CA) as per manufacturer’s instructions, followed by washing in
distilled water. All further steps were performed at room temperature in a hydrated chamber.
Slides were pre-treated with Peroxidase Block (DAKO USA, Carpinteria, CA) for 5 minutes
to quench endogenous peroxidase activity. For SNF5, monoclonal mouse anti-SNF5
antibody (BD Bioscience, clone 25/BAF47, Cat #612111) was applied at 1:100 in Dako
diluent for 1 hour. Slides were washed in 50-mM Tris-HCl, pH 7.4, and detected with anti-
mouse Envision+ kit (DAKO) as per manufacturer’s instructions. After further washing,
immunoperoxidase staining was developed using a DAB chromogen (DAKO) and
counterstained with hematoxylin. H&E and IHC-stained sections were evaluated
independently by experienced M.D. and D.V.M. pathologists (C.D.M.F. and A.B.R.) in
blinded fashion 23, 25.
Immunocytochemistry
Cells grown on glass coverslips were fixed in ice-cold 4% paraformaldehyde in PBS for 15
minutes then washed 3 times with PBS. Cells were then incubated in blocking buffer (PBS
with 5% normal goat serum and 0.1% Triton X-100) for 30 minutes at room temperature,
then with the following primary antibodies for 1 hour: anti-GFAP (1:2500; Dako), anti-
neurofilament (NFL; 1:1500, Chemicon), anti-cleaved caspase 3 (1:1000, Cell Signaling) or
anti-S100β (1:1000; Sigma), each diluted in blocking buffer. Following 3 washes in
blocking buffer, cells were incubated with fluorescently labeled secondary antibodies (Alexa
Fluor 488, 546; Molecular Probes, Eugene, OR, USA; diluted 1:2500 in blocking buffer) for
30 minutes and counterstained with 4',6-diamidino-2-phenylindole (DAPI) to label cell
nuclei. Cells were then washed 3 times in PBS and mounted in Fluoromount G (Southern
Biotech). Controls included sections incubated with no primary or secondary antibody and
also with mismatched secondary and primary antibodies. For determination of apoptotic
rates, 3 random fields of each cell line were counted.
Cytogenetic analyses
Cytogenetic analyses were carried out by KaryoLogic, Inc. (Research Triangle Park, NC)
following previously published protocols 26.
In vitro growth curves
The in vitro growth rates were carried out as previously described27. Briefly, cells (5×105)
were plated in normal growth medium in triplicate into 12-well cell dishes. At each
indicated time, cells were harvested by trypsinization, rinsed with PBS and resuspended in
1ml serum-free medium. Cell numbers were determined with a Coulter Counter apparatus.
In vivo growth assay
One × 108 cells for each cell line were harvested by trypsinization, rinsed with PBS and
resuspended in 1ml serum-free medium. Six-week old SoxN1 Nu/Nu female mice were
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inoculated subcutaneously on the left and right abdomen with 100µl (1×107 cells/site) of cell
suspension. Mice were monitored daily for signs of distress and measured for tumor
development 3X weekly. Mice were sacrificed when tumors reached a maximum dimension
(height, width or length) of 2 cm.
Results
Snf5+/− and TgT121;Snf5+/− mice develop both facial and CNS-MRTs
Our previous study showed a significant decrease in the average latency for MRT
development in TgT121;Snf5+/− mice compared to their Snf5+/− cohorts 28. We also
observed at least a ten-fold increase in the frequency of MRTs located around the dorsal
roots or spinal nerves within the spinal cord, most frequently near the thoracolumbar
junction in the TgT121;Snf5+/− mice 28. We did not detect a significant change in the rate of
appearance of facial MRTs and no evidence of intracranial MRT development.
A previous report by Klochlendler-Yeivin et al. indicated that genetic background may
influence the frequency and the site of MRT development in Snf5+/− mice 29. In our
previous study, the Snf5+/+ mice were maintained on a stable but undetermined mixed
genetic background of C57BL/6 and 129/SvJ 23, 28, 29. In order to minimize the effects of
genetic background upon MRT development, we generated Snf5−/+ mice on a congenic
C57BL/6 background by backcrossing for greater than 9 generations. We then crossed these
mice to the TgT121 mice on a BDF1 background and followed TgT121;Snf5+/− and Snf5+/−
F1 generation cohorts for up to 24 months. Similar to our previous study, TgT121;Snf5+/−
mice developed tumors at a significantly younger age than the Snf5+/− mice (mean= 8.3 vs.
20.2 months, p<.0001) (Table 1) 22.
As shown in our previous report, we did not observe a significant difference in the
penetrance of the MRTs between TgT121;Snf5+/− and Snf5+/− mice (Table 1) 28. Although
the early onset of MRTs in many TgT121;Snf5+/− mice precluded determination of the CPC
endpoint in these mice, we observed a comparable stage of CPC development at sacrifice to
that previously reported for our TgT121 mice 28. However, in constrast to our previous
findings, we did not observe MRTs located around the dorsal roots or spinal nerves near the
thoracolumbar junction 28. Instead, the Snf5+/− and TgT121;Snf5+/− F1 C57/BL6.BDF1 mice
developed an equal ratio of MRTs located in the soft tissues and in the brain (Table 1).
Mesenchymal/rhabdoid-type tumors arose in the jaw, proximal foreleg and nasal cavity,
whereas epithelial tumors with features of CPC were identified in the cerebellum and the
cerebrum. Morphologic differentiation of the two tumor phenotypes was confirmed by both
participating pathologists. Therefore, the cooperativity of pRbf and SNF5 loss in MRT
development again decreased tumor latency within tissues of the nervous system. However,
the sites of these tumors apparently differed on the new genetic background.
MRTs but not CPCs show loss of SNF5 expression
Our previous studies had shown that loss of SNF5 expression accompanied the appearance
of the MRTs in the TgT121;Snf5+/− mice 28. In contrast, we did not observe loss of the wild-
type SNF5 allele or protein expression in CPCs that arose in these mice 28. To confirm that
SNF5 loss only appeared in the MRTs in the TgT121;Snf5+/− mice, we carried out IHC to
assess its expression in representative tumors. In Figure 1, right column, we show the
histopathology of a representative CPC found in TgT121 mice 16. Virtually all of the tumor
cells show strong nuclear staining for SNF5 indicating retention of the wild-type Snf5 allele.
In contrast, the nuclei of the cells in representative malignant rhabdoid tumor show no
evidence of SNF5 expression (Figure 1, middle column). As we have previously observed,
the tumors display a significant level of SNF5-positive inflammatory cells that serve as
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internal positive controls 30(Figure 1, middle column). We also saw positive nuclear staining
for SNF5 in the unaffected areas of the brains of these mice (Figure 1, left column).
Establishment of MRT cell lines from TgT121;Snf5+/− and Snf5+/− mice
Cell lines established from primary tumors have proven useful tools for dissecting the
molecular events that lead to cellular transformation. In the case of MRT, a significant
number of human MRT cell lines exist that have proven useful for understanding the role of
SNF5 loss in tumor development8, 31. However, despite the development of multiple
GEMMs based upon constitutive or conditional loss of SNF5 expression, no mouse MRT
cell lines have been reported. Therefore, we attempted to establish cell lines from primary
MRTs of both genotypes and were able to successfully grow 3 cell lines.
The 2 cell lines, RTM639f and RTM658f, resembled the typical cellular morphology
observed in many human MRT cell lines32 (Figure 2A). However, the RTM614f cell line
showed a more fibroblast-like morphology, reminiscent of a 3T3 derived cell line.
Therefore, we checked the genotype of each cell line to determine their consistency with the
tumor of origin. As shown in Figure 2B, the RTM639f cell line, derived from a Snf5+/−
MRT of the brain, and the RTM658f cell line, derived from a TgT121;Snf5+/− MRT near the
scapula, had each lost the wild-type Snf5 allele. However, the RTM614f cell line, derived
from an explant of a TgT121;Snf5+/− facial MRT, had retained the wild-type Snf5 allele
(Figure 2B). In agreement with the genotype results, both RTM658 and RTM639 do not
express SNF5 protein while the RTM614 cell line does (Figure 2C). Furthermore, both
RTM614 and RTM658 express the T121 protein, in agreement with our previous
report 28(Figure 2C). Therefore, we did not further characterize the RTM614 cell line
because it appeared to arise from stromal contamination. The MRT cell lines have now
grown for >20 passages in culture suggesting that they have attained immortality.
Characterization of MRT cell lines
Differentiation marker expression—We examined both cell lines for expression of
proteins associated with human MRTs. As shown in Figure 2D, the RTM658 and RTM639
cell lines expressed α-smooth muscle actin (αSMA), a protein reported as commonly
expressed in human MRT cell lines 33. Surprisingly, they also showed high levels of the
cyclin-dependent kinase inhibitor (CDKI) protein p16INK4A, a gene that remains silenced by
polycomb in many human MRT cell lines 24, 34. As controls, we also confirmed expression
of another CDKI protein, p18INK4C, and a SWI/SNF complex member BAF180/PBRM1
(Figure 2D).
A recent report implicated neural stem cells as the cell of origin for MRTs 35. Furthermore,
early histological characterizations of human MRTs demonstrated expression of neuronal
differentiation markers 36. Our previous analyses of protein expression in primary tumors
from Snf5+/− and TgT121;Snf5+/− mice had also suggested a neuronal origin for these
tumors 28, 30. We could not detect expression of two markers associated with neural
differentiation, NESTIN and SOX2, in the RTM639f and RTM658f cell lines (Figure 2D).
However, both cell lines expressed glial fibrillary acidic protein (GFAP), a protein
expressed by both mature glial cells and by neural progenitor cells (Figure 2E). The
RTM658f cell line also expressed S100β, which is associated with differentiated Schwann
cells in the peripheral nervous system and neurons in the central nervous system, and NF-L,
a marker associated with differentiated neurons. In contrast, the RTM639f cell line weakly
expressed NF-L in a subset of cells and lacked S100β protein. These differences in neural
marker differentiation may reflect the different anatomical site of origin of the 2 cell lines
(see Discussion).
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Cytogenetics—Human MRTs often display little evidence of genomic instability either at
the level of cytogenetics or molecular markers 37, 38. Therefore, we examined the karyotypes
of the mouse MRT cell lines by standard cytogenetic G-banding analysis to determine
whether they had undergone significant genomic instability. As shown in Figure 3A, the
RTM639f cell line retained a near diploid karyotype with a minimal number of
chromosomal abnormalities (Supplemental Figure 1A). This relatively minor effect on gross
genomic stability mirrors that observed in human MRT cell lines 39, 40. In contrast, the
RTM658f cell line showed a hypotetraploid chromosome count although with minimal
aberrant chromosomal rearrangements (Figure 3B, Supplemental Figure 1B). We analyzed
the RTM-658f cell line at 2 different passage numbers, 21 and 52. While the relative
chromosomal contribution to each karyotype was similar at both passages, we noted the
appearance of dicentrics suggesting a significant level of genomic instability. We only
examined the karyotype of the RTM-639f cell line at passage 23. However, we did not find
any evidence of genomic instability in this cell line. The difference between the 2 cell lines
may reflect the loss of Rb family function via expression of the T121 protein in the
RTM658f cell line.
In Vitro growth properties—Due to the apparent differences in the cellular morphology
displayed by the two cell lines, we determine whether they show different growth properties
in culture. As shown in Figure 4A, the cell lines showed rates of proliferation in culture. The
RTM-658f possessed a doubling time of 27.1 hours (± 0.24) while the RTM-639f cell line
has a doubling time of 30.4 hours (± 0.67). We also determined the rate of apoptosis in each
cell line by assessing cleavage of caspase 3 by immunofluorescence as previously
described 41 (Supplementary Figure 2). As with the growth rates, the apototic rates for the 2
cells lines did not differ significantly- RTM-658f: 0.2% (± 0.1%) vs. RTM-639f: 0.4% (±
0.2%).
In Vivo tumorigenicity—We next assessed the ability of each cell line to form tumors in
immunocompromised mice after subcutaneous inoculation. Figure 4B shows that both cell
lines rapidly formed tumors in nu/nu mice necessitating sacrifice of the animals within one
month after inoculation. Furthermore, the RTM639f cell line, derived from the Snf5+/−
mouse, proved far more aggressive than theT121-expressing, TgT121;Snf5+/−-derived
RTM658f cell line.
The histopathologies of the original malignant rhabdoid tumors from which the MRT cell
lines were derived are shown in the top panels of Figure 5 and the tumors formed by each
cell line are shown in bottom panels. The histology resembled the architecture of the tumor
from which each cell line was originally derived (Figure 5- compare top and bottom panels).
We confirmed genotyping and protein expression data from Figure 2B and C by IHC,
demonstrating a loss of SNF5 protein expression in the original tumors (Figure 5- middle
panels). Therefore, these cell lines recapitulate the basic in vivo growth properties of the
original MRT counterparts.
Discussion
While MRTs present as aggressive, embryonic neoplasms that may appear in a wide range
of anatomical locations, almost all share an alteration of the SNF5 gene resulting in protein
loss 31. Genetically engineered mouse models based upon inactivation of the Snf5 gene have
also shown a range of anatomical sites of MRT development including legs, face, spinal
cord and brain 23, 29, 42. However, the penetrance of tumor development as well as the range
of anatomical sites with tumors differed among these reports.
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One difference among the Snf5+/− GEMM characterized in the previous studies lies in the
mixed genetic background of the mice. While all the models came from a cross between
C57BL/6 and 129/SvJ mice, the actual contribution of each genome to the models is
unknown. Thus, the differences observed among the 3 reports may arise from a difference in
genetic background. Multiple reports have shown the influence of genetic background on
tumor development in GEMMs 43. Our current report supports this notion. While our
previous study demonstrated MRTs on the face and the spinal cord at an average age of 4.5
months in TgT121;Snf5+/− mice, our current study showed MRTs on the face and in the
brain at an average age of 7.8 months (28, Table 1). The major difference between the two
studies comes from the genetic backgrounds of the Snf5+/− mice- mixed C57BL/6×129SvJ
vs. congenic C57BL/6. These results implicate genetic modifier loci that may influence both
the rate of MRT development as well as the site of tumor initiation.
Primary human MRTs and human MRT cell lines display a remarkable chromosome and
genomic stability 37, 38, 40, 44. In contrast, most mouse cell lines, including well-
characterized “normal” cells such as NIH/3T3 and C3H10T1/2, possess aneuploid
karyotypes 45, 46. However, like their human counterparts, the mouse MRT cell line
RTM639 remained primarily diploid with only a minor amount of chromosome
rearrangements. Interestingly, Lu et al. did not observe chromosomal instability in a Tg121
GEMM for choroid plexus development 22. However, they did not examine cell lines
established from these mice.
The cell of origin for MRTs remains unclear. Previous reports of Snf5+/− GEMMs have
suggested that tumors have arisen from cells of neural crest origin in the mice 28, 42.
Consistent with the in vivo tumor characterization, we observe expression of neural
differentiation markers in the mouse MRT cell lines (Figure 2). Of interest, the RTM639 cell
line, derived from the brain, showed a differentiation expression pattern consistent with a
neural progenitor 47–49. However, the RTM658 cell line, derived from a facial tumor,
showed a more differentiated pattern, expressing both neuronal and glial markers. Whether
this difference reflects the site of origin of the tumors or the presence of the TgT121
transgene in the RTM658 cell line remains an open question.
The availability of GEMMs and cell lines that could lead to the identification of secondary
genetic changes that influence the clinical course of MRT development in human patients
offers the opportunity to address several important issues. Patients with MRT show a range
of responses to treatment from little benefit to multiple years of remission. The differences
in the rate of tumor development and the penetrance observed in these GEMMs may provide
insight into the genetic loci that influence how these tumors respond to therapy. We are
currently developing Snf5+/− mice on a congenic 129SvJ background to directly compare
the development of MRTs to the C57BL/6 background. Questions also remain about the
relationship among MRTs (AT/RTs) that develop in different organ sites i.e. do they
represent the same tumor or different tumors with a common genetic defect. An expanding
repitoire of GEMMs that develop MRTs in different sites may offer the means to
experimentally address this issue by tracking the cell of origin in each model. Finally, the
development of the mouse MRT cell lines will present a tractable system for rapidly testing
new treatments in culture paired with a matched clinically relevant in vivo model.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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This study characterizes the first MRT cell lines derived from genetically engineered
mouse models as well as the effects of genetic background on in vivo MRT development.
These cell lines will provide critical new reagents for dissecting the mechanisms that
drive the epigenetic instability found in these unique tumors as well as serve as biological
models for testing novel drugs for the treatment of this aggressive disease.
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Figure 1. Histopathology and SNF5 immunohistochemistry of normal brain, MRT and CPC in
TgT121;Snf5
+/− mice
Paraffin-embedded sections of representative MRT, CPC and normal brain samples were
stained for histology by H&E by standard methods (top row). Additional sections were also
assessed for expression of SNF5 by immunohistochemistry as outlined in the Material and
Methods in the bottom row. The red arrows denote SNF5-positive infilitrating immune cells
while the black arrows show the larger nuclei of the MRT cells. The middle row
demonstrates staining of sections in the absence of the primary anti-SNF5 monoclonal
antibody.
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Figure 2. In vitro characterization of mouse MRT cell lines
A) Photomicroscopy of the MRT-derived cell lines; B) Primary tumor and cell line
genotyping- DNA was isolated from primary MRT samples and associated cell lines and
assayed for the presence of wild-type and mutant SNF5 alleles by PCR analysis. The
RTM639 and RTM639-2 cell lines were established independently in different flasks from
the same MRT. RTM639f, RTM614f and RTM658f cell lines were subsequently isolated
from the original cell line flask as a detached cell population to minimize fibroblast
contamination. RTM658f (early)- early passage, (late)- late passage; C) T121 expression-
T121 protein expression in each cell line was assessed by Western blot analysis as described
in the Material and Methods; D) Expression of differentiation and cell cycle markers-
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Protein expression of cell cycle regulators p16INK4A and p18INK4C, the SWI/SNF complex
member and tumor suppressor BAF180/PBRM1 and the differentiation markers smooth
muscle actin (SMA), SOX2 and NESTIN were determined by standard Western blotting
protocols; E) Neural differentiation- Neural differentiation was assessed by
immunocytochemistry for NESTIN, GFAP and NF-L as described in the Material and
Methods. Cells were visualized by fluorescence microscopy.
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Figure 3. Representative karyotype of mouse MRT cell lines
Identification and characterization of the chromosome content of each cell line was
performed using the standard G-banding method. Representative karyotypes of RTM-639f,
passage #23 and RTM-658f, passage #52 are shown.
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Figure 4. In vitro and in vivo growth rates of mouse MRT cell lines
(A) Each cell line was plated at 5x105 cells per well. On the designated days, cells were
removed by treatment with trypsin-EDTA and counted by a Coulter Counter apparatus. A
representative growth curve from duplicate biological experiments is presented. (B) Each
cell line was inoculated S.C. into 6 SoxN1 Nu/Nu female mice and measured for tumor
development 3X weekly. Each line represents the tumor growth of one subcutaneous
inoculation per animal.
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Figure 5. Histopathology and SNF5 immunochemistry of primary MRTs and MRT cell lines
Paraffin-embedded sections from the original tumors developed in the Snf5+/− mouse 639
and the Snf5+/−;T121, mouse 658 were stained for histology by H&E by standard methods
(top row). Additional sections were also assessed for expression of SNF5 by
immunohistochemistry as outlined in the Material and Methods in the middle row. In the
bottom row, paraffin-embedded sections from tumors formed by the RTM639f and
RTM658f cell lines in Nu/Nu mice were stained for histology by H&E as described above.
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